Daiichi Sankyo Company and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.
Daiichi Sankyo has announced that Ken Keller will join the company as President of its...
Daiichi Sankyo has announced that Glenn Gormley, MD, PhD, has been named corporate President and...
Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch SurveyMarch 4, 2013 7:59 am | News | Comments
More than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
Daiichi Sankyo Co. said today it will set up a company later this month to develop a drug to treat Duchenne muscular dystrophy with capital aid from government-backed and private investment funds The state-backed Innovation Network Corp. of Japan and Mitsubishi UFJ Capital Co. will put up most of the expenses to develop the drug.
Six current and former female sales representatives are accusing drugmaker Daiichi Sankyo of gender discrimination in a $100 million class action lawsuit. The lawsuit states the women are trying to end employment discrimination for themselves and several hundred other female sales reps who...
ArQule and its partner Daiichi Sankyo of Japan said they stopped a late-stage study of tivantinib as a treatment for non-small cell lung cancer. The companies said patients who were being treated with tivantinib and Tarceva, another cancer drug, were not living longer than patients treated with Tarceva and a placebo.
The 140,000 square foot facility will package some of the company’s portfolio of marketed products for cardiovascular and metabolic therapies ...
Daiichi Sankyo Company, Ltd. and NGM Biopharmaceuticals, Inc. announced today that they have entered into a research collaboration and license agreement to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.
Daiichi Sankyo, Inc. announced that Mahmoud Ghazzi, MD, PhD has joined Daiichi Sankyo Pharma Development (DSPD) as its new executive vice president of drug development for the Americas region.
AstraZeneca today announced a co-promotion agreement in Japan with Daiichi Sankyo for denosumab for the treatment of bone disorders stemming from bone metastasis.
Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited, under which Pieris will apply its proprietary Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets.
Daiichi Sankyo, Inc. (DSI) announced today that John P. Gargiulo has been appointed President and CEO of the company. Effective today, Mr. Gargiulo succeeds Joseph P. Pieroni who is retiring after leading Daiichi Sankyo Group's U.S. commercial operations for the past 14 years.
Daiichi Sankyo Company has concluded an agreement to acquire Plexxikon Inc., a privately held pharmaceutical company based in Berkeley, California with a late-stage oncology product, PLX4032, as well as a promising pipeline and technology platform.
Daiichi Sankyo, Inc. has announced the acquisition of a 140,000 square foot facility in Bethlehem Township, Pennsylvania from Amcor, a global packaging manufacturer. This acquisition, worth $10.25MM, enables DSI to leverage existing resources to more cost-effectively supplement its operations rather than build a new facility.
AstraZeneca today announced an agreement with Daiichi Sankyo for the co-promotion and supply of NEXIUM (esomeprazole magnesium), a proton pump inhibitor, in Japan.
ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology.
FDA Approves TribenzorT, A Three-In-One Combination Product for the Treatment of High Blood PressureJuly 26, 2010 4:38 am | News | Comments
Daiichi Sankyo, Inc. announced today that the FDA approved TRIBENZORT (olmesartan medoxomil, amlodipine, hydrochlorothiazide), a new three-in-one combination product
Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. CollaborationJuly 12, 2010 7:36 am | News | Comments
Accumetrics, Inc., Daiichi Sankyo, Inc, and Eli Lilly and Company announced today that the companies have entered into a strategic collaboration in the United States to raise awareness about antiplatelet therapy and the role of platelet function testing.
Daiichi Sankyo, Inc. announced today that the FDA has approved the hypertension treatment Benicar (olmesartan medoxomil) for use in children and adolescents
ERIKA KINETZ AP Business Writer MUMBAI, India (AP) — India's largest drug maker, Ranbaxy Laboratories Ltd., on Monday reported a $24 million quarterly profit as emerging market sales and cost cutting helped compensate for sharply falling U.S. sales. Net profit for the three months ending Sept.
MARIA CHENG AP Medical Writer BARCELONA, Spain (AP) — Heart patients taking a commonly prescribed cocktail of blood thinners and heartburn drugs may not be at increased risk of heart attacks or other problems, a new study says.
Biota Holdings Announces Successful Phase III Asian Clinical Trials of Its Second Generation Flu TreatmentAugust 10, 2009 5:09 am | News | Comments
Biota Holdings Limited has announced successful results from the Asian Phase III clinical trials of CS-8958, its second generation influenza treatment.
INDIANAPOLIS (AP) — Eli Lilly and Co. said Wednesday the blood thinner Effient has finally reached U.S. pharmacy shelves. The Indianapolis company said Effient is now available across the United States.
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europefor Postmenopausal Osteoporosis (PMO)July 27, 2009 12:22 pm | News | Comments
Amgen and GlaxoSmithKline have announced a collaboration inwhich the companies will share commercialization of Amgen's monoclonalantibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia,New Zealand and Mexico once the product is approved in these countries.
MATTHEW PERRONE AP Business Writer WASHINGTON (AP) — The FDA on Friday approved a highly anticipated blood thinner from Eli Lilly, though the drug must carry the agency's sternest warning because of its bleeding risks.
Daiichi Sankyo Co., Ltd. and Ranbaxy Laboratories Limited recently announced that Mr. Malvinder Mohan Singh has stepped down from the positions of Chairman, CEO and Managing Director of Ranbaxy with immediate effect. Mr.
Daiichi Sankyo, Inc. has announced that the FDA hasapproved the combination treatment AZOR(R) (amlodipine and olmesartanmedoxomil) as initial or 'first-line' therapy in patients likely to needmultiple antihypertensive agents to achieve their blood pressure (BP) goals.
- Page 1